Aptamers in Therapeutics

Area of Science:

• Biotechnology
• Molecular Biology
• Drug Discovery

Background:

• Aptamers are single-stranded DNA or RNA molecules generated through Systematic Evolution of Ligands by Exponential Enrichment (SELEX).
• They possess advantages like high temperature stability, cost-effective production, and high target affinity and selectivity.
• These characteristics make aptamers promising alternatives to monoclonal antibodies in diagnostics and therapeutics.

Purpose of the Study:

• To highlight the potential of aptamers as alternatives to monoclonal antibodies.
• To showcase the diverse applications of aptamers in diagnostics and therapeutics.
• To provide an overview of aptamer development for various diseases and infections.

Main Methods:

• Systematic Evolution of Ligands by Exponential Enrichment (SELEX) is the primary method for aptamer selection.
• Aptamers are generated against specific targets, such as proteins and viruses.
• Clinical and therapeutic applications are evaluated based on aptamer performance.

Main Results:

• Aptamers have been successfully developed against vascular endothelial growth factor 165 for age-related macular degeneration.
• The first FDA-approved aptamer-based drug, Macugen, demonstrates therapeutic potential.
• Aptamers are being developed for blood clotting proteins, cancer markers, and viral infections.

Conclusions:

• Aptamers represent a versatile class of molecules with significant potential in both diagnostic and therapeutic applications.
• Their advantages over traditional antibody-based approaches are driving innovation in medicine.
• Continued research and development are expanding the scope of aptamer utility across various medical fields.